News

Harvard Business Review2d
Be a Better Ally
In the United States and many other parts of the world, we’re finally engaging in substantive conversations about a once untouchable issue: white male privilege. The #MeToo and Black Lives ...
BMJ4d
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
This single-arm, open-label study was not powered to compare tumour types. Fresh and archival biopsies were accepted, so biomarker profiles from some biopsies were not time-matched to the start of the ...
rmdopen.bmj4d
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase ...
BE COMPLETE and its open-label extension, BE VITAL, demonstrated that bimekizumab was well tolerated in patients with PsA and TNFi-IR up to 52 weeks; the overall safety profile was consistent with ...